Among the 21 CRC patients with stage II adenocarcinoma, 11 (52%) exhibited above 2-fold increase in SOCS1 expression in tumours, whereas SOCS1 under-expression in tumours was denoted in only 2 (9%) patients. This evidence concerns the gene SOCS1 and adenocarcinoma.